Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis.

Boden EK, Canavan JB, Moran CJ, McCann K, Dunn WA, Farraye FA, Ananthakrishnan AN, Yajnik V, Gandhi R, Nguyen DD, Bhan AK, Weiner HL, Korzenik JR, Snapper SB.

Crohns Colitis 360. 2019 Jul;1(2):otz009. doi: 10.1093/crocol/otz009. Epub 2019 Jun 7.

2.

Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases.

Axelrad JE, Bazarbashi A, Zhou J, Castañeda D, Gujral A, Sperling D, Glass J, Agrawal M, Hong S, Lawlor G, Hudesman D, Chang S, Shah S, Yajnik V, Ananthakrishnan A, Khalili H, Colombel JF, Itzkowitz S; New York Crohn’s and Colitis Organization.

Clin Gastroenterol Hepatol. 2019 Jul 11. pii: S1542-3565(19)30735-9. doi: 10.1016/j.cgh.2019.06.042. [Epub ahead of print]

PMID:
31302306
3.

Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases.

Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brislawn CJ, Casero D, Courtney H, Gonzalez A, Graeber TG, Hall AB, Lake K, Landers CJ, Mallick H, Plichta DR, Prasad M, Rahnavard G, Sauk J, Shungin D, Vázquez-Baeza Y, White RA 3rd; IBDMDB Investigators, Braun J, Denson LA, Jansson JK, Knight R, Kugathasan S, McGovern DPB, Petrosino JF, Stappenbeck TS, Winter HS, Clish CB, Franzosa EA, Vlamakis H, Xavier RJ, Huttenhower C.

Nature. 2019 May;569(7758):655-662. doi: 10.1038/s41586-019-1237-9. Epub 2019 May 29.

4.

Challenges in IBD Research: Novel Technologies.

Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D'Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, Braun J, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, Michelassi F.

Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S24-S30. doi: 10.1093/ibd/izz077.

PMID:
31095703
5.

Survey on practice patterns in imaging utilization in patients with Crohn's disease.

Baliyan V, Kordbacheh H, Serrao J, Gee MS, Yajnik V, Sahani DV, Kambadakone AR.

Clin Imaging. 2019 Mar - Apr;54:91-99. doi: 10.1016/j.clinimag.2018.12.003. Epub 2018 Dec 14.

PMID:
30597412
6.

Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.

Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD; Clinical Research Alliance of the Crohn’s and Colitis Foundation.

Gastroenterology. 2018 Oct;155(4):1098-1108.e9. doi: 10.1053/j.gastro.2018.06.046. Epub 2018 Jun 30.

7.

Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases.

Lee JY, Wasinger VC, Yau YY, Chuang E, Yajnik V, Leong RW.

Proteomes. 2018 Mar 31;6(2). pii: E17. doi: 10.3390/proteomes6020017. Review.

8.

The colonic epithelium plays an active role in promoting colitis by shaping the tissue cytokine profile.

Lyons J, Ghazi PC, Starchenko A, Tovaglieri A, Baldwin KR, Poulin EJ, Gierut JJ, Genetti C, Yajnik V, Breault DT, Lauffenburger DA, Haigis KM.

PLoS Biol. 2018 Mar 29;16(3):e2002417. doi: 10.1371/journal.pbio.2002417. eCollection 2018 Mar.

9.

Integrated in vivo multiomics analysis identifies p21-activated kinase signaling as a driver of colitis.

Lyons J, Brubaker DK, Ghazi PC, Baldwin KR, Edwards A, Boukhali M, Strasser SD, Suarez-Lopez L, Lin YJ, Yajnik V, Kissil JL, Haas W, Lauffenburger DA, Haigis KM.

Sci Signal. 2018 Feb 27;11(519). pii: eaan3580. doi: 10.1126/scisignal.aan3580.

10.

Integrin αM activation and upregulation on esophageal eosinophils and periostin-mediated eosinophil survival in eosinophilic esophagitis.

Vimalathas P, Farris A, Letner D, Deshpande V, Yajnik V, Shreffler W, Garber J.

Immunol Cell Biol. 2018 Apr;96(4):426-438. doi: 10.1111/imcb.12018. Epub 2018 Mar 6.

PMID:
29424023
11.

Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases.

Borren NZ, Conway G, Garber JJ, Khalili H, Budree S, Mallick H, Yajnik V, Xavier RJ, Ananthakrishnan AN.

J Crohns Colitis. 2018 Apr 27;12(5):525-531. doi: 10.1093/ecco-jcc/jjx154.

12.

Comparison of Stromal Vascular Fraction with or Without a Novel Bioscaffold to Fibrin Glue in a Porcine Model of Mechanically Induced Anorectal Fistula.

Dryden GW, Boland E, Yajnik V, Williams S.

Inflamm Bowel Dis. 2017 Nov;23(11):1962-1971. doi: 10.1097/MIB.0000000000001254.

PMID:
28945635
13.

Clinical Predictors and Natural History of Disease Extension in Patients with Ulcerative Proctitis.

Walsh E, Chah YW, Chin SM, Lochhead P, Yajnik V, Denmark V, Garber JJ, Khalili H.

Inflamm Bowel Dis. 2017 Nov;23(11):2035-2041. doi: 10.1097/MIB.0000000000001214.

14.

Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease.

Borren NZ, Conway G, Tan W, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN.

Inflamm Bowel Dis. 2017 Jul;23(7):1234-1239. doi: 10.1097/MIB.0000000000001133.

15.

Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases.

Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, Cleland T, Xavier RJ.

Cell Host Microbe. 2017 May 10;21(5):603-610.e3. doi: 10.1016/j.chom.2017.04.010.

16.

Effect of oral tobacco use and smoking on outcomes of Crohn's disease in India.

Arora U, Ananthakrishnan AN, Kedia S, Bopanna S, Mouli PV, Yadav DP, Makharia GK, Yajnik V, Ahuja V.

J Gastroenterol Hepatol. 2018 Jan;33(1):134-140. doi: 10.1111/jgh.13815.

PMID:
28475826
17.

Imaging in Patients with Crohn's Disease: Trends in Abdominal CT/MRI Utilization and Radiation Exposure Considerations over a 10-Year Period.

Kordbacheh H, Baliyan V, Serrao J, Gee MS, Yajnik V, Sahani DV, Kambadakone AR.

Inflamm Bowel Dis. 2017 Jun;23(6):1025-1033. doi: 10.1097/MIB.0000000000001088.

PMID:
28426472
18.

Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis.

Bopanna S, Ananthakrishnan AN, Kedia S, Yajnik V, Ahuja V.

Lancet Gastroenterol Hepatol. 2017 Apr;2(4):269-276. doi: 10.1016/S2468-1253(17)30004-3. Epub 2017 Feb 21. Review.

19.

Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.

Ananthakrishnan AN, Donaldson T, Lasch K, Yajnik V.

Inflamm Bowel Dis. 2017 Jun;23(6):882-893. doi: 10.1097/MIB.0000000000001099. Review.

20.

Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.

Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V, Korzenik J.

Dig Dis Sci. 2017 Jun;62(6):1590-1596. doi: 10.1007/s10620-017-4549-3. Epub 2017 Mar 29.

Supplemental Content

Loading ...
Support Center